You just read:

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

News provided by

Amgen

Oct 26, 2018, 19:54 ET